22:35 , Jul 19, 2019 |  BioCentury  |  Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

A draft FDA guidance for heart failure endpoints could spark investment and accelerate development of cardiovascular therapies. But companies still don’t have a clear sense of when and whether they’ll need to gather mortality data...
17:33 , Mar 2, 2018 |  BC Week In Review  |  Financial News

BioMedPartners closes third fund at CHF100M

BioMedPartners (Basel, Switzerland) closed its BioMedInvest III fund at CHF100 million ($107 million). The firm plans to invest the fund in 12-15 private early to mid-stage pharmaceutical, medical device and diagnostics companies in Switzerland, Germany...
18:11 , Mar 1, 2018 |  BC Extra  |  Financial News

BioMedPartners closes third fund

BioMedPartners closed its BioMedInvest III fund at CHF100 million ($107 million). The firm plans to invest the fund in 12-15 private early to mid-stage pharmaceutical, medical device and diagnostics companies in Switzerland, Germany and neighboring...
22:03 , Aug 31, 2017 |  BioCentury  |  Finance

Fund fine-tuning

BioMedPartners is fine-tuning its strategy for its third fund to focus more on therapeutics investments, where the firm has seen most of its biggest returns. The Swiss VC told BioCentury BioMedInvest III has reached an...